Existing horizon scanning activities could be strengthened to aid budget planning in the context of high upfront cost therapies such as gene therapies. International collaborations could be leveraged ...

The Office of Health Economics is delighted to host the Health Economists’ Study Group Summer Meeting, which will run from 30th June – 2nd July 2025. Founded in 1972, the Health Economists’ Study ...

Meindert is a highly respected expert in the field of Health Technology Assessment (HTA) with more than 25 years’ experience in the field. Before starting as an independent advisor, Meindert was ...

Today marks Rare Disease Day 2025. This time last year we published an Article entitled “Why do we care about rare?”, summarising the origins of rare disease day, the fundamental ambition – to strive ...

Measuring and valuing health outcomes is arguably what makes health economics such a unique and sometimes controversial discipline. The idea of putting a numerical value on an individual’s health ...

Matthias is a Principal Economist at OHE. His expertise and research interests include regulatory science and policy, the value of pharmaceuticals for patients and society, and the economics of ...

Sulayman’s skills include health economic theory and economic modelling with a particular aptitude for econometric analysis and quantitative data. His primary ...

Charlotte is a communications and external affairs expert with over a decade of experience in global non-profits and academia with a specialist focus on health and development. Working with partners ...

Dr. Jacoline Bouvy is the Programme Director of Medicines Evaluation at the National Institute for Health and Care Excellence (NICE). She is responsible for the delivery of medicines guidance produced ...